Chemours Co — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Chemours reported Q2 2026 net sales of $1.591B (−1% YoY), with net loss of $274M ($1.81/share) vs. prior-year loss of $380M ($2.53/share). Adjusted EBITDA was $247M (−5% YoY) but near guidance; Adjusted EPS $0.42 vs. $0.61. Free cash flow improved 128% to $114M. Net leverage declined to 4.4x from 4.6x; company paid down €230M of term debt using Kuan Yin land sale proceeds ($273M gain) and organic cash. Guidance maintained: FY2026 sales +1–5%, Adjusted EBITDA $775–825M, target net leverage ~3.8x by year-end.
Why this rating
Modest operational decline offset by improved liquidity/deleveraging. Q2 sales flat; Adj. EBITDA −5%. Land sale gain one-time. Within guidance; ordinary execution. Material leverage action against $1.7B market cap but operational underperformance routine.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.